ArticleBMC oral health2026
Bone-Morphology (BM) classification: a novel staging system for mandibular conventional ameloblastoma, a multicenter retrospective study.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fibroblast growth factor receptor signaling in head and neck tumors: molecular pathogenesis and potential therapeutic targets.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundAmeloblastoma is the most common odontogenic epithelial tumor, characterized by local aggressiveness and high recurrence rates. Current management lacks a practical staging system to guide surgical decisions, making it challenging to balance radical resection with functional preservation.
methodsThis retrospective cohort study developed and validated a novel bone destruction and radological Morphology (BM) staging system for mandibular conventional ameloblastoma. We analyzed 649 patients from three tertiary centers (2005–2024), categorizing them into BM stages I-III. Recurrence-free survival (RFS) was analyzed using Kaplan–Meier methods and log-rank tests.
resultsThe BM staging system effectively stratified recurrence risk and guided surgical choices. The 5-year RFS rates decreased significantly with advancing stage: stage I (71.9%), stage II (46.4%), and stage III (24.5%) (P < 0.0001). In stage I, both curative resection surgery (CRS) and curettage and fenestration decompression (CFD) achieved 100% 5-year RFS. For stage II patients, CRS was marginally superior to CFD. For stage III, CRS led to significantly better outcomes (88.2%) than other approaches (P < 0.0001). In stages I and II, patients treated with fenestration decompression or local curettage had significantly worse prognosis than those receiving CRS or CFD.
conclusionsThe BM staging system provides effective prognostic stratification and guides surgical decisions. Modified conservative surgery (CFD) is appropriate for stage I, while curative resection is recommended for stage III to minimize recurrence risk. For stage II patients, the choice between CRS and CFD should weigh the benefit of lower recurrence against the risk of jaw discontinuity and functional impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.